(PDF) Copy-Neutral Loss of Heterozygosity Is Prevalent and

Copy-Neutral Loss of Heterozygosity Is Prevalent and a Late Event in the Pathogenesis of FLT3/ITD AML

Blood Cancer Journal - United States

doi 10.1038/bcj.2014.27

Full Text

Open PDF

Abstract

Available in full text

Date

May 1, 2014

Authors

D L Stirewalt

E L Pogosova-Agadjanyan

K Tsuchiya

J Joaquin

S Meshinchi

Publisher

Springer Science and Business Media LLC

Related search

Donor HSCs With a Preexisting ASXL1-mutation Led to the Development of FLT3-ITD Positive AML in the Donor and FLT3-ITD Negative AML in the Recipient After Unrelated Transplant

Bone Marrow Transplantation

Transplantation

Hematology

2018

English

NOX-driven ROS Formation in Cell Transformation of FLT3-ITD-positive AML

Experimental Hematology

English

Clonal Evolution and Clinical Significance of Copy Number Neutral Loss of Heterozygosity of Chromosome Arm 6p in Acquired Aplastic Anemia

English

Clonal Evolution and Clinical Significance of Copy Number Neutral Loss of Heterozygosity of Chromosome Arm 6p in Acquired Aplastic Anemia

English

Comprehensive SNP Array Study of Frequently Used Neuroblastoma Cell Lines; Copy Neutral Loss of Heterozygosity Is Common in the Cell Lines but Uncommon in Primary Tumors

English

Uniparental Isodisomy Caused Autosomal Recessive Diseases: NGS‐based Analysis Allows the Concurrent Detection of Homogenous Variants and Copy‐neutral Loss of Heterozygosity

Molecular genetics & genomic medicine

Genetics

Molecular Biology

2019

English

DOCK2: A Novel FLT3/ITD Leukemia Drug Target

Oncotarget

Oncology

2017

English

Overcoming AC220 Resistance of FLT3-ITD by SAR302503

English

Mutation Analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 Patients With MDS or Secondary AML

English

Amanote Research

Copy-Neutral Loss of Heterozygosity Is Prevalent and a Late Event in the Pathogenesis of FLT3/ITD AML

Blood Cancer Journal - United States

doi 10.1038/bcj.2014.27

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Donor HSCs With a Preexisting ASXL1-mutation Led to the Development of FLT3-ITD Positive AML in the Donor and FLT3-ITD Negative AML in the Recipient After Unrelated Transplant

NOX-driven ROS Formation in Cell Transformation of FLT3-ITD-positive AML

Clonal Evolution and Clinical Significance of Copy Number Neutral Loss of Heterozygosity of Chromosome Arm 6p in Acquired Aplastic Anemia

Clonal Evolution and Clinical Significance of Copy Number Neutral Loss of Heterozygosity of Chromosome Arm 6p in Acquired Aplastic Anemia

Comprehensive SNP Array Study of Frequently Used Neuroblastoma Cell Lines; Copy Neutral Loss of Heterozygosity Is Common in the Cell Lines but Uncommon in Primary Tumors

Uniparental Isodisomy Caused Autosomal Recessive Diseases: NGS‐based Analysis Allows the Concurrent Detection of Homogenous Variants and Copy‐neutral Loss of Heterozygosity

DOCK2: A Novel FLT3/ITD Leukemia Drug Target

Overcoming AC220 Resistance of FLT3-ITD by SAR302503

Mutation Analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 Patients With MDS or Secondary AML